• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU
Click for more information
0.35% $20.17

NEUREN PHARMACEUTICALS LIMITED

Market Cap $2.578B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
NEU
Neuren Media and Analyst Coverage
20 21 22
09:25 1.2K 650K
09:25 Last post  giarc63 Comments Created with Sketch.  1.2K  Views Created with Sketch.  650K 
NEU
Acadia
10 11 12
06:20 683 318K
06:20 Last post  Fordy23 Comments Created with Sketch.  683  Views Created with Sketch.  318K 
NEU
Share Price
181 182 183
26/07/24 10K 5.0M
26/07/24 Last post  htae39 Comments Created with Sketch.  10K  Views Created with Sketch.  5.0M 
NEU
Stop the Rort (revisited) 		26/07/24 13 3.2K
26/07/24 Last post  Trademil Comments Created with Sketch.  13  Views Created with Sketch.  3.2K 
NEU
Ann: Neuren to participate in upcoming US investor conferences 		25/07/24 7 3.4K
25/07/24 Last post  Agent-86 Comments Created with Sketch.  7  Views Created with Sketch.  3.4K 
NEU
Katelin’s Turn is HERE!!!
3 4 5
25/07/24 251 139K
25/07/24 Last post  jimbovb Comments Created with Sketch.  251  Views Created with Sketch.  139K 
NEU
Angelman trial
2
23/07/24 70 37K
23/07/24 Last post  w_i_z_z_a Comments Created with Sketch.  70  Views Created with Sketch.  37K 

See All Discussions arrow Created with Sketch.

Timeline

Neuren to participate in upcoming US investor conferences
25 Jul 09:10
 
Ceasing to be a substantial holder
19 Jul 11:27
 
Neuren receives Rare Pediatric Disease Designation from FDA
19 Jul 09:59
 
Final Director's Interest Notice - T Scott
02 Jul 16:49
 
Application for quotation of securities - NEU
17 Jun 16:28
 
Change of Director's Interest Notice - J Basile
13 Jun 13:16
 
View More arrow Created with Sketch.

Featured News

FMG Quarterly & half yearly reports: Drives Newmont up, Ampol flat, while Fortescue plunges 2.6%
right-arrow Created with Sketch.
RHK Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit
right-arrow Created with Sketch.
NEWS Real estate dynamics & changes raise investor doubt
right-arrow Created with Sketch.
BGL Bellevue aims for 45% production increase by FY 2028, announces $150M placement
right-arrow Created with Sketch.
1CG One Click Group surpasses $3M in revenue YTD with 40% growth
right-arrow Created with Sketch.
NEWS Nine staff strike as Paris Olympic coverage begins
right-arrow Created with Sketch.

(20min delay)
Last
$20.17 		Change
0.070(0.35%) 		Mkt cap ! $2.578B
Open High Low Value Volume
$20.39 $20.53 $20.14 $4.102M 202.5K

Buyers (Bids)

No. Vol. Price($)
2 249 $20.15
 

Sellers (Offers)

Price($) Vol. No.
$20.31 790 1
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
Last
$20.22 		  Change
0.070 ( 0.32 %)
Open High Low Volume
$20.28 $20.52 $20.15 35704
Last updated 15.59pm 26/07/2024 ?
NEU (ASX) Chart

Top Stories

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Biotech company Tissue Repair Ltd (ASX:TRP) has seen its share price rise more than 30% on news it had gained TGA (Therapeutic Goods Administration) approval for its advanced wound healing gel TR Pro+, which contains yeast-derived active ingredient Glucoprime.At 13:25 AEDT, shares in Tissue Repai...
ASX Market Open: ASX200 to rise for Friday session | July 26 The ASX200 is set to rise 0.4% according to ASX futures around 8.30am on the final day of the week.
Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision Horizon Minerals (ASX:HRZ) has announced its independent ore reserve for Boorara, flagging 49.5Koz of gold production over a 14mth LOM.The company expects the project to fetch just short of $20M.All permits are in place, haulage contracts are @well advanced” and an ore sales...
Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit Red Hawk Mining (ASX:RHK) has announced an upgrade for the mineral resource incorporating the company’s Eagle Deposit.@Red Hawk is pleased to announce an MRE for Direct Shipping Ore (DSO) for the Eagle deposit at the 100%- owned Blacksmith Iron Ore Project of 71.1Mt at 57.4% Fe,&C...
Capital raisings wrap: Brainchip, Ovanti, Lake and VHM Tech sector companies Ovanti Ltd and Brainchip Holdings Ltd joined Lake Resources Ltd and VHM Ltd in capital raising efforts.

Featured News

TRP Tissue Repairs soars nearly 32% on TGA approval for wound healing gel
right-arrow Created with Sketch.
FMG Quarterly & half yearly reports: Drives Newmont up, Ampol flat, while Fortescue plunges 2.6%
right-arrow Created with Sketch.
1CG One Click Group surpasses $3M in revenue YTD with 40% growth
right-arrow Created with Sketch.
MIN MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned
right-arrow Created with Sketch.
FHE Frontier Energy lines up $215 million debt financing from Mike Cannon-Brookes-backed Infradebt
right-arrow Created with Sketch.
BGL Bellevue aims for 45% production increase by FY 2028, announces $150M placement
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.